ANI Pharmaceuticals
ANIP
181 hedge funds and large institutions have $751M invested in ANI Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 34 closing their positions.
436% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $248K
1.56% more ownership
Funds ownership: 65.09% → 66.65% (+1.6%)
4% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $766M → $751M (-$15.6M)
9% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 34
2% less funds holding
Funds holding: 185 → 181 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$15.3M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$12.7M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$11M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.62M |
| 5 |
JP Morgan Chase
New York
|
+$7.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$15.8M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$9.58M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$8.43M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$6.49M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$5.17M |
ANIP Hedge Fund Activity: Q4 2023 in Review
181 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2023, worth a combined $751M — down 2% from $766M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ANIP and 31 opened new positions — a net loss of 3 holders — while 53 trimmed existing stakes and 55 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $15.3M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $15.8M sold.
- 181 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2023, down from 185 in Q3 2023.
- Funds reported $751M of ANI Pharmaceuticals stock for Q4 2023, down 2% quarter-over-quarter.
- 31 funds opened new ANI Pharmaceuticals positions in Q4 2023 and 34 closed out, a net change of -3 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2023 was Rubric Capital Management (New York), an estimated $15.3M added.
- The largest ANI Pharmaceuticals seller in Q4 2023 was AIGH Capital Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q4 2023.